Search

everythinglearnresearchcommunity

for

Search:↓

PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.

Epidermal growth factor helps hair stem cells grow by activating specific cell pathways.

Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.

Erlotinib can cause nonscarring hair loss and itchy skin.

Erlotinib may cause scarring hair loss.

EGFR hyperactivation increases sebaceous gland size and sebum production in mice.

Targeting EGFR may help reduce hair loss from chemotherapy.

EGFR helps mouse hair follicles stop growing by reducing certain growth regulators.

EGFR inhibitors can cause skin issues, but managing them is important for treatment success.

Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.

EGFR inhibitors often cause dry, brittle hair and eyebrow/eyelash changes.

Targeting FGFR-1 with antisense oligonucleotides may help treat baldness by increasing hair follicle activity.

Cetuximab often causes skin problems, but they can be managed without stopping treatment.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.

A new method quickly detects hair changes from EGFR inhibitors using a microscope.

Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.

Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

Lasers can help reduce skin side effects from cancer treatment.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

Gefitinib can cause scalp skin issues and permanent hair loss.

Blocking EGFR can lead to hair loss due to inflammation and stem cell damage.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.